Focal therapy for prostate cancer has evolved over 2 decades, with advances in imaging, patient selection, treatment modalities, and clinical trials.
Vol.27/No.9
Maurie Markman, MD, discusses conflicts of interest in cancer care.
Advertisement
Advertisement
Trending on OncLive
1
August Roundup of FDA Approvals in Oncology: Daraxonrasib Highlights 5 Decisions to Know
2
New Biomarker-Driven Regimens Prompt Debate Over Treatment Intensification in Advanced Prostate Cancer
3
TP53 Status and Treatment Toxicity Burden Guide Sequencing in EGFR-Mutated NSCLC
4
FDA Grants Breakthrough Therapy Designation to JBS-003 for Radiation De-Escalation in HPV+ Oropharyngeal Cancer
5